Answers are grounded in this paper and cite their sources.
Review outlines translational hurdles and safety profiles of nanoparticle therapeutics across major disease models, highlighting pathways toward standardized clinical regulation.
Nanotechnology has emerged as a transformative approach in modern medicine, offering innovative strategies for disease diagnosis, treatment, and prevention. Nanoparticles, typically ranging from 1 to 100 nm in size, possess unique physicochemical properties that enable targeted drug delivery, enhanced therapeutic efficacy, and reduced systemic toxicity. This review provides a comprehensive overview of the major types of nanoparticles used in disease treatment, including lipid-based, polymeric, metallic, magnetic, and carbon-based nanoparticles. Their applications across various disease domains, such as cancer, infectious diseases, neurological disorders, and cardiovascular conditions, are discussed. In addition, the benefits and limitations associated with nanoparticle-based therapies, including safety concerns and regulatory challenges, are critically examined. Finally, future perspectives on the clinical translation and advancement of nanomedicine are highlighted.
No takes yet. Share an insight, caveat, or question.
El-Said et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: